Enzybiotics LYSSTAPH-S and LYSDERM-S as Potential Therapeutic Agents for Chronic MRSA Wound Infections

Varování

Publikace nespadá pod Ekonomicko-správní fakultu, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.
Autoři

VACEK Lukáš KOBZOVÁ Šárka ČMELÍK Richard PANTŮČEK Roman JANDA Lubomír

Rok publikování 2020
Druh Článek v odborném periodiku
Časopis / Zdroj Antibiotics
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www https://www.mdpi.com/2079-6382/9/8/519
Doi http://dx.doi.org/10.3390/antibiotics9080519
Klíčová slova enzyme therapy; enzybiotics; lysostaphin; LYSSTAPH-S; endolysin; LYSDERM-S; MRSA
Přiložené soubory
Popis Antibacterial antibiotic therapy has played an important role in the treatment of bacterial infections for almost a century. The increasing resistance of pathogenic bacteria to antibiotics leads to an attempt to use previously neglected antibacterial therapies. Here we provide information on the two recombinantly modified antistaphylococcal enzymes derived from lysostaphin (LYSSTAPH-S) and endolysin (LYSDERM-S) derived from kayvirus 812F1 whose target sites reside in the bacterial cell wall. LYSSTAPH-S showed a stable antimicrobial effect over 24-h testing, even in concentrations lower than 1 mu g/mL across a wide variety of epidemiologically important sequence types (STs) of methicillin-resistantStaphylococcus aureus(MRSA), especially in the stationary phase of growth (status comparable to chronic infections). LYSDERM-S showed a less potent antimicrobial effect that lasted only a few hours at concentrations of 15 mu g/mL and higher. Our data indicate that these antimicrobial enzymes could be of substantial help in the treatment of chronic MRSA wound infections.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.